Effect of Dehydroepiandrosterone Administration in Patients With Poor Ovarian Response According to the Bologna Criteria
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02132559|
Recruitment Status : Completed
First Posted : May 7, 2014
Last Update Posted : May 7, 2014
Women with low ovarian reserve typically respond less well to the drugs used to stimulate the ovary during IVF treatment and produce fewer eggs and, as a result, are less likely to fall pregnant either naturally or after fertility treatment. The ideal stimulation regimen for poor responders is currently unknown.
Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy chances for poor responders, and is now utilized by approximately one third of all IVF centers world-wide. However, the current clinical evidence for DHEA on improvement of ovarian response and IVF outcome is insufficient. The validity of the results of the former studies, especially the varied inclusion criteria used to specify poor responders, is a subject of debate. Recently a uniform definition on poor ovarian response, the Bologna criteria, has been proposed by the European Society for Human Reproduction and Embryology(ESHRE). However, no studies have been performed study to evaluate the potential effects of DHEA supplementation according to these standards.
The purpose of this study is to assess the impact of DHEA supplementation on IVF outcome of poor ovarian responders that fulfill the Bologna criteria.
|Condition or disease||Intervention/treatment|
|Study Type :||Observational|
|Actual Enrollment :||386 participants|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
DHEA administration,no treatment
The patients of study group received DHEA 25 mg orally,three times a day before the IVF cycle. Except for IVF, the control group of patients did not receive any pre-treatment.
Other Name: dehydroepiandrosterone
- ongoing pregnancy rates [ Time Frame: 12 weeks after gestation. ]
- Clinical pregnancy rate [ Time Frame: 28 days after the embryo transfer ]
- the number of retrieved oocytes [ Time Frame: 36-37 hrs after hCG administration ]
- Fertilization rate [ Time Frame: on day 1 after oocyte retrieval ]
- Cleavage rate [ Time Frame: on day 2 or 3 after oocyte retrieval ]
- Implantation rate [ Time Frame: 28 days after the embryo transfer ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02132559
|Reproductive Medicine Center, Tongji Hospital, Tongji Medicine College, Huazhong University of Science and Technology|
|Wuhan, Hubei, China, 430030|
|Study Director:||Guijin Zhu||Reproductive Medicine Center, Tongji Hospital, Tongji Medicine College, Huazhong University of Science and Technology|